Jefferies Group Reaffirms Buy Rating on Infinity Pharmaceuticals (INFI)

By admin | 6 years ago

Infinity Pharmaceuticals (NASDAQ: INFI)‘s stock had its “buy” rating reaffirmed by Jefferies Group (NYSE: JEF) in a research note issued on Wednesday.

Infinity Pharmaceuticals traded down 3.97% on Wednesday, hitting $13.05. Infinity Pharmaceuticals has a 52-week low of $5.50 and a 52-week high of $13.53. The company’s market cap is $350.9 million.

Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company’s lead product candidate, IPI-504 (retaspimycin hydrochloride), is an intravenously administered small molecule inhibitor of heat shock protein 90 (Hsp90).

About the author